Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart Tags
Bone & JointCardiovascularCase Study & ProceedingCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTISmart Search
Clinical study of PCSO-524 (ANTINOL™) as neutraceutical in canine allergic skin disease
This study included 31 allergic dogs with chronic pruritis with other skin diseases excluded.
Dogs were split into 3 treatment groups based on degree of pruritis, distribution, extension of the lesions and skin and coat condition; Group 1: mild, Group 2: moderate, and Group 3: severe.
All dogs received PCSO-524 loading dose 10 mg/kg q12hr PO for 2 weeks followed by a maintenance dose of 10 mg/kg q24hr PO.
All dogs were evaluated at 2, 4, 8, 12 and 16 weeks for clinical response. The assessment made by the owners (PVAS Score) and Vets (CADESI-03 score).
Antinol® Case Study Contest 2017
10 Case Reports using PCSO-524® in combination with the treatment regimen for dogs and cats.
Pharmalink International Ltd. and Vetz Petz® would like to thank everyone involved in this 2017 Antinol® Case Study Contest competition and pay homage to our Professors and Veterinarians who have assisted in the judging of the competition.
This 2017 contest was very special with the inclusion of Professor Duncan Lascelles and the wonderful innovation of the live poll that the audience took part in to choose the Vets choice and favorite presentation.
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted